Axsome, Teva and AUVELITY

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Teva Pharmaceuticals,
Axsome settles Auvelity patent litigation with Teva
Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a proposed generic version of Auvelity. Read more here.
Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute with peer Teva
Axsome Therapeutics Shares Rise After Agreement with Teva Pharmaceuticals Ends Litigation
Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after Sept. 30, 2039, if no pediatric exclusivity is granted.
Axsome Therapeutics stock rises on patent litigation settlement
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) surged 15% following the announcement of a settlement agreement with Teva Pharmaceuticals that resolves patent litigation over its flagship product, AUVELITY®.
TD ups Axsome target, sees takeout speculation on patent settlement
TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $155 and keeps a Buy rating on the shares. The company
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Axsome stock target raised to $190 on Teva litigation resolution
TD Cowen adjusted its outlook on Axsome Therapeutics (NASDAQ:AXSM), a $6.16 billion market cap company, by increasing the price target to $190 from the previous $155, while maintaining a Buy rating on ...
FiercePharma21h
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Why Axsome Therapeutics Stock Is Skyrocketing Today
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...
BofA raises Axsome stock target on extended Auvelity exclusivity
BofA Securities analyst Jason Gerberry increased the price target for Axsome Therapeutics (NASDAQ:AXSM) shares to $167 from the previous $143, while reiterating a Buy rating on the stock. This aligns ...
BioPharma Dive19h
Axsome secures top drug’s future with Teva patent settlement
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.
Axsome Therapeutics price target raised to $195 from $137 at Mizuho
Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following ...
FiercePharma11d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Deutsche Bank sets $176 price target on Axsome stock with buy rating
Deutsche Bank (ETR:DBKGn) initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) shares, assigning a Buy rating and setting a price target of $176.00. The new coverage comes with a positive outlook ...